The legacy theme of general health and science information has long served as a foundation for public understanding of environmental risks. Within this broad context, discussions of chemical exposures and their potential health effects have been framed in universal terms, emphasizing broad preventive principles. As we shift focus toward occupational settings, the concern becomes more specific: workers in mass production industries may encounter chemical agents at higher concentrations and with greater frequency than the general population. This transition from general awareness to workplace-specific risk assessment is critical. Among the various chemical exposures studied, benzene has emerged as a compound of particular interest due to its widespread use in industrial processes. The question of whether benzene exposure can lead to the development of acute myeloid leukemia represents a focused inquiry within occupational health. This pivot from general health education to targeted occupational concern allows for a more precise evaluation of exposure scenarios, regulatory thresholds, and monitoring practices. The following discussion will examine the relationship between benzene exposure in mass production environments and the risk of acute myeloid leukemia, without delving into specific mechanistic pathways.
Benzene is a well-established myelotoxin and recognized human carcinogen. Chronic exposure to benzene is acknowledged to increase the risk for the onset of acute myeloid leukemia (AML), myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The causal relationship between occupational benzene exposure and AML has been established in previous studies (https://pubmed.ncbi.nlm.nih.gov/38727681/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with an increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Furthermore, a meta-analysis of childhood cancers found an elevated risk of AML associated with benzene exposure, with an odds ratio of 1.22 (95% CI: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/).
Acute myeloid leukemia is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid precursor cells in the bone marrow and peripheral blood. Clinical presentation typically includes symptoms related to bone marrow failure, such as fatigue, pallor, infection, and bleeding, as well as signs of extramedullary involvement. Diagnosis is confirmed by bone marrow biopsy showing at least 20% blasts of myeloid lineage, along with cytogenetic and molecular testing to classify subtypes and guide treatment. The disease can arise de novo or secondary to prior chemotherapy, radiation, or exposure to myelotoxic agents like benzene.
Benzene is a volatile organic compound that is absorbed primarily through inhalation, but also through dermal and oral routes. After absorption, benzene is metabolized in the liver, primarily by cytochrome P450 2E1, to reactive intermediates such as benzene oxide, phenol, hydroquinone, and muconaldehyde. These metabolites can circulate to the bone marrow, where they exert toxic effects. Benzene is acknowledged as a myelotoxin, and chronic exposure can augment the risk for hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/). Reported adverse effects include hematotoxicity, such as leukopenia, anemia, and thrombocytopenia, as well as genotoxicity and immunosuppression.
Multiple mechanistic pathways have been identified that link benzene exposure to the development of AML. Possible mechanisms include a genotoxic effect, an action on oxidative stress and inflammation, and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). The mode of action for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical adverse outcomes, the morbidity and mortality caused by myelodysplastic syndromes and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/).
Given the established causal relationship between benzene exposure and AML, the adequacy of warnings is a critical risk consideration. Occupational exposure limits have been set in many jurisdictions, but the evidence indicates that even low-level exposure, such as 1 μg/m³, is associated with an increased risk of AML in children (https://pubmed.ncbi.nlm.nih.gov/41485753/). The Swiss National Cohort study found that occupational exposure to benzene is associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). These findings underscore the need for clear and comprehensive warnings to workers and the public about the risks of benzene exposure, including the potential for AML.
For patients diagnosed with AML who have a history of benzene exposure, causation considerations are relevant. The evidence supports that benzene is a causal factor for AML, particularly in occupational settings with exposure levels of 10 ppm or more (https://pubmed.ncbi.nlm.nih.gov/33429013/). However, AML is a heterogeneous disease with multiple potential causes, including genetic predisposition, prior chemotherapy, and other environmental exposures. In individual cases, establishing causation requires a detailed exposure history, assessment of latency, and exclusion of other known risk factors. The presence of benzene-induced hematotoxicity or genetic toxicity in peripheral blood may support a causal link.
The timeline between benzene exposure and the development of AML can vary. The mode of action includes multiple key events, such as hematotoxicity and genetic toxicity, which can be observed in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). These early events may precede the clinical onset of AML by months to years. The latency period for benzene-induced AML is typically several years, but cases have been reported with shorter latencies following high-level exposure. The Swiss National Cohort study examined mortality records linked to census data, suggesting that long-term follow-up is necessary to capture the full impact of exposure (https://pubmed.ncbi.nlm.nih.gov/38727681/).
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Benzene is a recognized human carcinogen and chronic exposure increases the risk of developing acute myeloid leukemia (AML). Studies have established a causal relationship, particularly at occupational exposure levels of 10 ppm or more (https://pubmed.ncbi.nlm.nih.gov/33429013/). Even low-level exposure, such as 1 μg/m³, has been associated with increased AML risk in children (https://pubmed.ncbi.nlm.nih.gov/41485753/).
Benzene is metabolized in the liver to reactive intermediates that circulate to the bone marrow, causing hematotoxicity, genotoxicity, and immunosuppression. Multiple mechanistic pathways are involved, including genotoxic effects, oxidative stress, and inflammation (https://pubmed.ncbi.nlm.nih.gov/34069279/). These early key events can lead to the development of AML over time.
The latency period typically spans several years, but can be shorter following high-level exposure. Early events such as hematotoxicity and genetic toxicity may be observed in peripheral blood months to years before clinical onset (https://pubmed.ncbi.nlm.nih.gov/33429013/). Long-term follow-up is necessary to capture the full impact.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.